247 related articles for article (PubMed ID: 21795085)
1. Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies.
Vladutiu GD; Isackson PJ; Kaufman K; Harley JB; Cobb B; Christopher-Stine L; Wortmann RL
Mol Genet Metab; 2011; 104(1-2):167-73. PubMed ID: 21795085
[TBL] [Abstract][Full Text] [Related]
2. RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms.
Isackson PJ; Wang J; Zia M; Spurgeon P; Levesque A; Bard J; James S; Nowak N; Lee TK; Vladutiu GD
Pharmacogenomics; 2018 Nov; 19(16):1235-1249. PubMed ID: 30325262
[TBL] [Abstract][Full Text] [Related]
3. RYR1-Related Myopathies: Clinical, Histopathologic and Genetic Heterogeneity Among 17 Patients from a Portuguese Tertiary Centre.
Samões R; Oliveira J; Taipa R; Coelho T; Cardoso M; Gonçalves A; Santos R; Melo Pires M; Santos M
J Neuromuscul Dis; 2017; 4(1):67-76. PubMed ID: 28269792
[TBL] [Abstract][Full Text] [Related]
4. Compound RYR1 heterozygosity resulting in a complex phenotype of malignant hyperthermia susceptibility and a core myopathy.
Kraeva N; Heytens L; Jungbluth H; Treves S; Voermans N; Kamsteeg E; Ceuterick-de Groote C; Baets J; Riazi S
Neuromuscul Disord; 2015 Jul; 25(7):567-76. PubMed ID: 25958340
[TBL] [Abstract][Full Text] [Related]
5. A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene.
Løseth S; Voermans NC; Torbergsen T; Lillis S; Jonsrud C; Lindal S; Kamsteeg EJ; Lammens M; Broman M; Dekomien G; Maddison P; Muntoni F; Sewry C; Radunovic A; de Visser M; Straub V; van Engelen B; Jungbluth H
J Neurol; 2013 Jun; 260(6):1504-10. PubMed ID: 23329375
[TBL] [Abstract][Full Text] [Related]
6. RYR1-related myopathies: a wide spectrum of phenotypes throughout life.
Snoeck M; van Engelen BG; Küsters B; Lammens M; Meijer R; Molenaar JP; Raaphorst J; Verschuuren-Bemelmans CC; Straathof CS; Sie LT; de Coo IF; van der Pol WL; de Visser M; Scheffer H; Treves S; Jungbluth H; Voermans NC; Kamsteeg EJ
Eur J Neurol; 2015 Jul; 22(7):1094-112. PubMed ID: 25960145
[TBL] [Abstract][Full Text] [Related]
7. Identification and Functional Analysis of RYR1 Variants in a Family with a Suspected Myopathy and Associated Malignant Hyperthermia.
Schiemann AH; Roesl C; Pollock N; Langton E; Bulger T; Stowell KM
J Neuromuscul Dis; 2020; 7(1):51-60. PubMed ID: 31903994
[TBL] [Abstract][Full Text] [Related]
8. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
[TBL] [Abstract][Full Text] [Related]
9. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing.
Ibarra M CA; Wu S; Murayama K; Minami N; Ichihara Y; Kikuchi H; Noguchi S; Hayashi YK; Ochiai R; Nishino I
Anesthesiology; 2006 Jun; 104(6):1146-54. PubMed ID: 16732084
[TBL] [Abstract][Full Text] [Related]
10. Core myopathies and malignant hyperthermia susceptibility: a review.
Brislin RP; Theroux MC
Paediatr Anaesth; 2013 Sep; 23(9):834-41. PubMed ID: 23617272
[TBL] [Abstract][Full Text] [Related]
11. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
McCarthy TV; Quane KA; Lynch PJ
Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
[TBL] [Abstract][Full Text] [Related]
12. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor.
Monnier N; Romero NB; Lerale J; Nivoche Y; Qi D; MacLennan DH; Fardeau M; Lunardi J
Hum Mol Genet; 2000 Nov; 9(18):2599-608. PubMed ID: 11063719
[TBL] [Abstract][Full Text] [Related]
13. Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.
Lawal TA; Wires ES; Terry NL; Dowling JJ; Todd JJ
Orphanet J Rare Dis; 2020 May; 15(1):113. PubMed ID: 32381029
[TBL] [Abstract][Full Text] [Related]
14. RYR1 mutations as a cause of ophthalmoplegia, facial weakness, and malignant hyperthermia.
Shaaban S; Ramos-Platt L; Gilles FH; Chan WM; Andrews C; De Girolami U; Demer J; Engle EC
JAMA Ophthalmol; 2013 Dec; 131(12):1532-40. PubMed ID: 24091937
[TBL] [Abstract][Full Text] [Related]
15. [Genetic of diseases by abnormal functioning of the skeletal muscle-calcium releasing complex].
Lunardi J; Monnier N
Rev Neurol (Paris); 2004 May; 160(5 Pt 2):S70-7. PubMed ID: 15269663
[TBL] [Abstract][Full Text] [Related]
16. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
[TBL] [Abstract][Full Text] [Related]
17. Core myopathies and risk of malignant hyperthermia.
Klingler W; Rueffert H; Lehmann-Horn F; Girard T; Hopkins PM
Anesth Analg; 2009 Oct; 109(4):1167-73. PubMed ID: 19762745
[TBL] [Abstract][Full Text] [Related]
18. Mutation screening of the RYR1-cDNA from peripheral B-lymphocytes in 15 Swedish malignant hyperthermia index cases.
Broman M; Gehrig A; Islander G; Bodelsson M; Ranklev-Twetman E; Rüffert H; Müller CR
Br J Anaesth; 2009 May; 102(5):642-9. PubMed ID: 19346234
[TBL] [Abstract][Full Text] [Related]
19. A study of a family with the skeletal muscle RYR1 mutation (c.7354C>T) associated with central core myopathy and malignant hyperthermia susceptibility.
Taylor A; Lachlan K; Manners RM; Lotery AJ
J Clin Neurosci; 2012 Jan; 19(1):65-70. PubMed ID: 22030266
[TBL] [Abstract][Full Text] [Related]
20. An Assessment of Penetrance and Clinical Expression of Malignant Hyperthermia in Individuals Carrying Diagnostic Ryanodine Receptor 1 Gene Mutations.
Ibarra Moreno CA; Hu S; Kraeva N; Schuster F; Johannsen S; Rueffert H; Klingler W; Heytens L; Riazi S
Anesthesiology; 2019 Nov; 131(5):983-991. PubMed ID: 31206373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
